Extend your brand profile by curating daily news.

HeartBeam to Host Q1 2026 Earnings Call, Provide Updates on Commercial Launch and AI Programs

By Advos
HeartBeam Inc. will report first-quarter 2026 results on May 13 and update investors on its limited commercial launch for arrhythmia assessment, extended-wear patch development, and heart attack detection AI initiatives.

Found this article helpful?

Share it with your network and spread the knowledge!

HeartBeam to Host Q1 2026 Earnings Call, Provide Updates on Commercial Launch and AI Programs

HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter results for the period ended March 31, 2026. The company plans to provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection and artificial intelligence programs.

The call comes as HeartBeam advances its 3D ECG technology platform, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. The company's platform is designed to be the first cable-free device capable of collecting ECG signals in three non-coplanar directions and synthesizing them into a standard 12-lead ECG. This technology aims to enable portable cardiac monitoring outside medical facilities, allowing physicians to identify trends and acute conditions and direct patients to appropriate care.

HeartBeam holds over 20 issued patents related to its technology enablement, underscoring its intellectual property position in the cardiac monitoring space. The limited commercial launch for arrhythmia assessment represents the company's initial move to bring its 3D ECG technology to market, with extended-wear patch development and AI programs targeting broader applications such as heart attack detection.

Investors will be watching for updates on adoption metrics from the limited commercial launch, progress on the extended-wear patch, and milestones in the AI programs. The company's ability to secure reimbursement and provider partnerships will be critical for scaling its technology beyond the initial launch phase. The earnings call will provide a platform for management to address these factors and outline the roadmap for 2026 and beyond.

For more information, visit the company's newsroom at https://nnw.fm/BEAT and review the cleared indications for use at https://www.heartbeam.com/indications.

Advos

Advos

@advos